Active, not recruiting

3

154

Europe, Canada, US, RoW

Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo

Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.

Thyroid Eye Disease

07/24

03/25

Recruiting

3

438

Europe, Canada, US, RoW

N-acetylcysteine, Placebo

Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania

Retinitis Pigmentosa

12/28

12/28

Recruiting

1/2

21

US

ATSN-201

Atsena Therapeutics Inc.

X-linked Retinoschisis

10/25

10/29

Recruiting

2

38

US

Mesenchymal Stromal Cells, Control Solution

University of Illinois at Chicago, United States Department of Defense

Corneal Ulcer

09/25

09/25